• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Switching directly to biologic therapy when methotrexate fails is not cost effective for treating rheumatoid arthritis

byAndrew Cheung, MD MBA
May 31, 2017
in Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Biologic therapy had minimal additional benefits for patients compared to triple therapy.

2. When used as a first-line therapy, triple therapy resulted in significantly lower drug costs than biologic therapy.

Evidence Rating Level: 2 (Good)

Study Rundown: Guidelines currently recommend treating rheumatoid arthritis patients with biologic drugs, such as etanercept, following failure of conventional disease modifying anti-rheumatic drugs (DMARDs). However, biologic drugs are highly expensive. Recent studies have suggested that an alternate therapy, known as DMARD triple therapy (sulfasalazine, hydroxychloroquine, and methotrexate), is equally as effective as adding a biologic to methotrexate. Considering these results, the goal of this study was to determine the cost-effectiveness of etancercept-methotrexate, compared to triple therapy, as a first-line strategy for rheumatoid arthritis. Generally, the authors observed that initiating biologic therapy, without trying triple therapy, increases costs without significant benefit. There are several limitations to this study. First, there is limited data regarding the long-term benefits of triple therapy. Second, the model used to assess cost did not account for the possibility of certain adverse effects, which may differ between the 2 different therapies. Overall, the results of this study suggest that triple therapy is an important first-line therapy to initiate prior to switching to biologics.

Click to read the study, published in the Annals of Internal Medicine

Relevant Reading: A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial

RELATED REPORTS

#VisualAbstract Use of Certain Biologics or Disease Modifying Antirheumatic Drugs May Be Associated With Cancer Risk

Beneficial effects of hydroxychloroquine on blood lipids and glycated haemoglobin

Low-dose glucocorticoids for rheumatoid arthritis do not increase blood pressure

In-Depth [retrospective cohort]: The authors conducted a within-trial analysis based on the 353 participants of the Rheumatoid Arthritis Comparison of Active Therapies (RACAT) trial. They also performed a lifetime analysis, allowing them to extrapolate costs and outcomes by using a decision analytic cohort model. The outcomes assessed in this trial included incremental costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Following the within-trial analysis, it was observed that etanercept-methotrexate, as a first-line treatment, only resulted in marginally more QALYs. In contrast, etanercept-methotrexate had significantly higher drug costs compared to triple therapy. Additionally, the lifetime analysis indicated that first-line etanercept-methotrexate would cost $77 290, at the expense of only a 0.15 additional lifetime QALY.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: rheumatoid arthritis
Previous Post

No link between cesarean delivery and BMI in later childhood

Next Post

2 Minute Medicine Rewind May 29, 2017

RelatedReports

#VisualAbstract Use of Certain Biologics or Disease Modifying Antirheumatic Drugs May Be Associated With Cancer Risk
StudyGraphics

#VisualAbstract Use of Certain Biologics or Disease Modifying Antirheumatic Drugs May Be Associated With Cancer Risk

December 5, 2024
2 Minute Medicine Rewind January 28, 2019
Chronic Disease

Beneficial effects of hydroxychloroquine on blood lipids and glycated haemoglobin

November 8, 2024
UTI associated with increased risk of preeclampsia
Cardiology

Low-dose glucocorticoids for rheumatoid arthritis do not increase blood pressure

September 6, 2023
#VisualAbstract: Bariatric metabolic surgery more effective than medical therapy and lifestyle modifications for non-alcoholic steatohepatitis
StudyGraphics

#VisualAbstract: Bariatric metabolic surgery more effective than medical therapy and lifestyle modifications for non-alcoholic steatohepatitis

June 14, 2023
Next Post
ACP releases practice guidelines for the evaluation of suspected acute pulmonary embolism

2 Minute Medicine Rewind May 29, 2017

Hidradenitis suppurativa associated with increased risk of subclinical atherosclerosis

New prevalence estimates for hidradenitis suppurativa in the United States

Cardiac biomarkers unnecessarily ordered in emergency departments

Variation in markup of charges in emergency department and internal medicine services

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Structured exercise intervention improves survival in colon cancer patients
  • #VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
  • Cerebral embolic protection does not decrease stroke incidence in TAVI patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.